KR20220062084A - 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 - Google Patents

면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 Download PDF

Info

Publication number
KR20220062084A
KR20220062084A KR1020227012198A KR20227012198A KR20220062084A KR 20220062084 A KR20220062084 A KR 20220062084A KR 1020227012198 A KR1020227012198 A KR 1020227012198A KR 20227012198 A KR20227012198 A KR 20227012198A KR 20220062084 A KR20220062084 A KR 20220062084A
Authority
KR
South Korea
Prior art keywords
val
pro
ser
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012198A
Other languages
English (en)
Korean (ko)
Inventor
헬렌 치후이 카오
롤프 스피리그
아드리안 주어처
모렐리 아드리아나 바즈
Original Assignee
체에스엘 베링 렝나우 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 렝나우 아게 filed Critical 체에스엘 베링 렝나우 아게
Publication of KR20220062084A publication Critical patent/KR20220062084A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227012198A 2019-09-13 2020-09-11 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 Pending KR20220062084A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197287.6 2019-09-13
EP19197287 2019-09-13
PCT/EP2020/075432 WO2021048330A1 (en) 2019-09-13 2020-09-11 Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders

Publications (1)

Publication Number Publication Date
KR20220062084A true KR20220062084A (ko) 2022-05-13

Family

ID=68084577

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012198A Pending KR20220062084A (ko) 2019-09-13 2020-09-11 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체

Country Status (9)

Country Link
US (1) US20220332847A1 (https=)
EP (1) EP4028415A1 (https=)
JP (2) JP7734652B2 (https=)
KR (1) KR20220062084A (https=)
CN (1) CN114401985A (https=)
AU (1) AU2020344164A1 (https=)
BR (1) BR112022003713A2 (https=)
CA (1) CA3150680A1 (https=)
WO (1) WO2021048330A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
AU2017213117A1 (en) 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
US20210095006A1 (en) * 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

Also Published As

Publication number Publication date
JP7734652B2 (ja) 2025-09-05
US20220332847A1 (en) 2022-10-20
CN114401985A (zh) 2022-04-26
WO2021048330A1 (en) 2021-03-18
AU2020344164A1 (en) 2022-04-14
JP2022547692A (ja) 2022-11-15
BR112022003713A2 (pt) 2022-08-09
CA3150680A1 (en) 2021-03-18
JP2025124714A (ja) 2025-08-26
EP4028415A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
JP2025026880A (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
AU2015290673B2 (en) Novel anti-human Tie2 antibody
TWI733661B (zh) 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN113271972B (zh) 用于替代IVIG的多聚体杂交Fc蛋白
KR102884943B1 (ko) 개선된 항-flt3 항원 결합 단백질
CA3154756A1 (en) Gipr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
KR20230025673A (ko) CD3 및 FolR1에 결합하는 항체
EP4242232A1 (en) Bispecific antibody and use thereof
WO2021238932A1 (zh) 多特异性抗体及其应用
WO2018032639A1 (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
US20250051450A1 (en) Use of anti-pd-l1/cd47 bispecific antibody in treatment of diseases
TW201706303A (zh) 具有高親和性、結合性及專一性之結合轉形生長因子－β１的ｓｃＦｖ－Ｆｃ二聚體
CA3094286A1 (en) Gipr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
KR20250006896A (ko) 돌연변이체 경쇄 프레임워크 영역을 포함하는 단일 사슬 가변 단편
JP7823021B2 (ja) 抗ｐｄ－ｌ１抗体及びその応用
CA3096556A1 (en) Gcgr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
JP7734652B2 (ja) 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
US20220389120A1 (en) Multispecific antagonists
JP7674837B2 (ja) Ａｐｊ抗体及びｅｌａｂｅｌａとのその融合タンパク質並びにその医薬組成物及び用途
US20250368752A1 (en) Monoclonal antibody against tfpi and use thereof
CA3276730A1 (en) Fusion protein
CN121548586A (zh) 免疫治疗蛋白
HK40120543A (zh) 4-1bb结合蛋白
CN120230207A (zh) Pvrig结合蛋白、双特异性抗体及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902